Estrogen receptor (ER) expression has important implications for the prognosis and treatment of breast cancer. Patients with tumors that express ER have improved mortality, a longer disease-free interval, and are more likely to respond to hormonal therapy than patients with rumors that lack ER expression. In both breast carcinoma cell lines and primary breast tumors, ER expression is largely controlled by transcription of the ER gene. Transcription of the human ER gene is regulated by activity from the main ER promoter, P1, and at least two alternate ER promoters, both of which are active in breast carcinoma cell lines and primary breast cancers. Our previous work had identified the ERF-1 transcription factor involved in regulation of the main ER gene promoter in breast carcinomas. We have recently cloned ERF-1 and demonstrated that it is a member of the AP2 transcription factor family. The goal of this grant proposal is to determine the molecular basis for the improved prognosis associated with the hormone-responsive breast cancer phenotype. There are three aims of this grant proposal. Fist, we will identify the regulatory elements of alternate ER promoters. This will be accomplished by identifying the cap sites of the alternate ER transcripts, cloning genomic regions near the cap sites upstream of a receptor gene to identify cis-regulatory elements, and using gel shift and footprinting to identify factors regulating expression of the alternate ER transcripts. Second, we will demonstrate that ERF-1 regulates transcription from the main and alternate ER promoters.
This aim will be accomplished by co-transfecting the cloned ER promoters with the ERF-1 gene and by studying the effect of ERF-1 expression on the native ER gene in breast cancer lines. Third, we will characterize the expression of novel ER-regulated genes and determine their function in hormone-responsive tumors. This will be accomplished by cloning and sequencing cDNAs of novel ER-regulated genes and characterizing primary breast tumors for expression of these genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA077350-04S1
Application #
6479350
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1998-06-01
Project End
2002-02-28
Budget Start
2001-04-01
Budget End
2002-02-28
Support Year
4
Fiscal Year
2001
Total Cost
$88,650
Indirect Cost
Name
Stanford University
Department
Surgery
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Woodfield, George W; Horan, Annamarie D; Chen, Yizhen et al. (2007) TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 67:8439-43
McPherson, Lisa A; Woodfield, George W; Weigel, Ronald J (2007) AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma. J Surg Res 138:71-8
Stabach, P R; Thiyagarajan, M M; Woodfield, G W et al. (2006) AP2alpha alters the transcriptional activity and stability of p53. Oncogene 25:2148-59
McPherson, Lisa A; Loktev, Alexander V; Weigel, Ronald J (2002) Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 277:45028-33
Conroy, Andrew T; Sharma, Manju; Holtz, Ann E et al. (2002) A novel zinc finger transcription factor with two isoforms that are differentially repressed by estrogen receptor-alpha. J Biol Chem 277:9326-34
Schuur, E R; Loktev, A V; Sharma, M et al. (2001) Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 276:33554-60
Schuur, E R; McPherson, L A; Yang, G P et al. (2001) Genomic structure of the promoters of the human estrogen receptor-alpha gene demonstrate changes in chromatin structure induced by AP2gamma. J Biol Chem 276:15519-26
Ghosh, M G; Thompson, D A; Weigel, R J (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60:6367-75
Schuur, E R; Weigel, R J (2000) Monoallelic amplification of estrogen receptor-alpha expression in breast cancer. Cancer Res 60:2598-601
Nakatani, K; Thompson, D A; Barthel, A et al. (1999) Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274:21528-32

Showing the most recent 10 out of 13 publications